Posts moved from this thread: Trial of Long Covid treatment - AXA1125 from Axcella Therapeutics, 2021 ________________ Use of whole genome sequencing to determine genetic basis of suspected mitochondrial disorders: cohort study Abstract Objective To determine whether whole genome sequencing can be used to define the molecular basis of suspected mitochondrial disease. Design Cohort study. Setting National Health Service, England, including secondary and tertiary care. Participants 345 patients with suspected mitochondrial disorders recruited to the 100 000 Genomes Project in England between 2015 and 2018. Intervention Short read whole genome sequencing was performed. Nuclear variants were prioritised on the basis of gene panels chosen according to phenotypes, ClinVar pathogenic/likely pathogenic variants, and the top 10 prioritised variants from Exomiser. Mitochondrial DNA variants were called using an in-house pipeline and compared with a list of pathogenic variants. Copy number variants and short tandem repeats for 13 neurological disorders were also analysed. American College of Medical Genetics guidelines were followed for classification of variants. Main outcome measure Definite or probable genetic diagnosis. Results A definite or probable genetic diagnosis was identified in 98/319 (31%) families, with an additional 6 (2%) possible diagnoses. Fourteen of the diagnoses (4% of the 319 families) explained only part of the clinical features. A total of 95 different genes were implicated. Of 104 families given a diagnosis, 39 (38%) had a mitochondrial diagnosis and 65 (63%) had a non-mitochondrial diagnosis. Conclusion Whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31% after exclusion of common causes. Most diagnoses were non-mitochondrial disorders and included developmental disorders with intellectual disability, epileptic encephalopathies, other metabolic disorders, cardiomyopathies, and leukodystrophies. These would have been missed if a targeted approach was taken, and some have specific treatments. __________________________ On the subject of mitochondrial dysfunction, does anyone have a view on the possible usefulness of this just published work on whole genome sequencing by the MRC Mitochondrial Biology Unit and Departments of Clinical Neuroscience and Medical Genetics at Cambridge? Whole genome sequencing increases diagnosis of rare disorders by nearly a third https://www.cam.ac.uk/research/news...esearch&utm_medium=social&utm_source=linkedin I'm far out of my depth, but I wonder if this team could swap notes with Decode ME?